Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US-2017073429-A1 · Mar 16, 2017 · US
Binding proteins 1
US12312417B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12312417-B2 |
| Application number | US-202318164444-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2023 |
| Priority date | Jul 17, 2017 |
| Publication date | May 27, 2025 |
| Grant date | May 27, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to cell penetrating anti-DNA binding proteins. Compositions comprising these binding proteins may be may be useful for delivering agents to cells and treating diseases such as cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A cell penetrating antibody that binds to DNA, wherein the antibody comprises: a heavy chain variable region (VH) comprising: a complementarity determining region (CDR) 1 comprising the sequence NYGMH (SEQ ID NO: 1), a CDR2 comprising the sequence YISSGSSTIYYADSVKG (SEQ ID NO: 3), and a CDR3 comprising the sequence RGLLLDY (SEQ ID NO: 4); and a light chain variable region (VL) comprising: a CDR1 comprising the sequence RASKTVSTSSYSYMH (SEQ ID NO: 6), a CDR2 comprising the sequence YASYLES (SEQ ID NO: 7), and a CDR3 comprising the sequence QHSREFPWT (SEQ ID NO: 8), wherein the antibody is conjugated to a therapeutic compound. 2. The antibody of claim 1 , wherein: (i) the VH comprises a sequence at least 95% identical to the sequence as shown in any one of SEQ ID NOs: 21 to 23; and (ii) the VL comprises a sequence at least 95% identical to the sequence as shown in any one of SEQ ID NOs: 27 to 29. 3. The antibody of claim 1 , wherein the therapeutic compound comprises a cytotoxic agent. 4. The antibody of claim 1 , wherein the therapeutic compound comprises a chemotherapeutic agent. 5. The antibody of claim 1 , wherein the therapeutic compound comprises an anti-inflammatory agent. 6. The antibody of claim 1 , wherein the therapeutic compound comprises a radioisotope. 7. The antibody of claim 1 , wherein the antibody is conjugated to the therapeutic compound via a linker cleavable by cathepsin. 8. A composition comprising: the antibody of claim 1 ; and a pharmaceutically acceptable carrier. 9. A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of the antibody of claim 1 . 10. The method of claim 9 , wherein the cancer is glioblastoma. 11. The method of claim 9 , wherein the cancer is substantially BRCA2 deficient. 12. The method of claim 9 , wherein the cancer is substantially PTEN deficient. 13. A cell penetrating antibody that binds to DNA, wherein the antibody comprises: a heavy chain variable region (VH) comprising: a complementarity determining region (CDR) 1 comprising the sequence NYGMH (SEQ ID NO: 1), a CDR2 comprising the sequence YISSGSSTIYYADSVKG (SEQ ID NO: 3), and a CDR3 comprising the sequence RGLLLDY (SEQ ID NO: 4); and a light chain variable region (VL) comprising: a CDR1 comprising the sequence RASKTVSTSSYSYMH (SEQ ID NO: 6), a CDR2 comprising the sequence YASYLES (SEQ ID NO: 7), and a CDR3 comprising the sequence QHSREFPWT (SEQ ID NO: 8), wherein the antibody is conjugated to a nucleic acid. 14. The antibody of claim 13 , wherein: (i) the VH comprises a sequence at least 95% identical to the sequence as shown in any one of SEQ ID NOs: 21 to 23; and (ii) the VL comprises a sequence at least 95% identical to the sequence as shown in any one of SEQ ID NOs: 27 to 29. 15. A composition comprising: the antibody of claim 13 ; and a pharmaceutically acceptable carrier. 16. A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of the antibody of claim 13 . 17. The method of claim 16 , wherein the cancer is glioblastoma. 18. The method of claim 16 , wherein the cancer is substantially BRCA2 deficient. 19. The method of claim 16 , wherein the cancer is substantially PTEN deficient. 20. The antibody of claim 13 , wherein the antibody is conjugated to the nucleic acid via a linker cleavable by cathepsin.
Assignees
Inventors
Classifications
functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria · CPC title
Diabody or triabody · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Fab or Fab' · CPC title
F(ab')2 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12312417B2 cover?
- The present disclosure relates to cell penetrating anti-DNA binding proteins. Compositions comprising these binding proteins may be may be useful for delivering agents to cells and treating diseases such as cancer.
- Who is the assignee on this patent?
- Nucleus Therapeutics Pty Ltd, Univ Yale
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).